Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 6, 2014, Pages 629-637

  Gao, L ^a   Trinh, H N ^b   Li, J ^c   Nguyen, M H ^d  

^a STANFORD UNIVERSITY   (United States)

^b San Jose Gastroenterology   (United States)

^c PALO ALTO MEDICAL FOUNDATION   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; NUCLEOSIDE ANALOG; TENOFOVIR; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; GENE NUMBER; HELICOBACTER INFECTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; SEROCONVERSION; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS INHIBITION;

ADENINE; ADULT; ANTIVIRAL AGENTS; CALIFORNIA; COHORT STUDIES; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84894534287     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12629     Document Type: Article

References (33)

1. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
2. Lee WM,. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.
3. Chen CJ, Yang HI, Su J, et al,. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
4. Iloeje UH, Yang HI, Su J, et al,. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
5. Yang HI, Lu SN, Liaw YF, et al,. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-74.
6. Leung N,. Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues. Liver Int 2011; 31 (Suppl. 1): 85-9.
7. Papatheodoridis GV,. Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues. Liver Int 2011; 31 (Suppl. 1): 95-103.
8. Jenh AM, Pham PA,. Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther 2010; 8: 1079-92.
9. Honkoop P, de Man RA,. Entecavir: a potent new antiviral drug for hepatitis B. Expert Opin Investig Drugs 2003; 12: 683-8.
10. Colonno RJ, Rose R, Baldick CJ, et al,. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006; 44: 1656-65.
11. Tenney DJ, Rose RE, Baldick CJ, et al,. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-14.
12. Snow-Lampart A, Chappell B, Curtis M, et al,. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011; 53: 763-73.
13. Ha NB, Ha NB, Trinh HN, Nguyen HA, Nguyen KK, Nguyen MH,. Response to higher dose of entecavir 1.0 mg daily in patients with partial response to entecavir 0.5 mg daily. J Clin Gastroenterol 2013; 47: 461-5.
14. Ha NB, Ha HB, Chaung KT, et al,. Similar response to entecavir 0.5 and 1.0 mg in treatment-naïve chronic hepatitis B patients: a case-control study. Dig Dis Sci 2014; 59: 168-73.
15. Liaw YF, Sung JJ, Chow WC, et al,. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
16. Lok AS, Trinh H, Carosi G, et al,. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology 2012; 143: 619-28.e1.
17. Lok AS,. Drug therapy: tenofovir. Hepatology 2010; 52: 743-7.
18. Dogan UB, Kara B, Gumurdulu Y, Soylu A, Akin MS,. Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Turk J Gastroenterol 2012; 23: 247-52.
19. Guzelbulut F, Ovunc AO, Oetinkaya ZA, et al,. Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B. Hepatogastroenterology 2012; 59: 477-80.
20. Maratea D, Fadda V, Trippoli S, Messori A,. Letter: first-line monotherapies for chronic hepatitis B-indirect comparison between entecavir and tenofovir. Aliment Pharmacol Ther 2013; 37: 583-5.
21. Dakin H, Fidler C, Harper C,. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Value Health 2010; 13: 934-45.
22. Wiens A, Lenzi L, Venson R, et al,. Comparative efficacy of oral nucleoside or nucleotide analog monotherapy used in chronic hepatitis B: a mixed-treatment comparison meta-analysis. Pharmacotherapy 2013; 33: 144-51.
23. Woo G, Tomlinson G, Nishikawa Y, et al,. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and bayesian meta-analyses. Gastroenterology 2010; 139: 1218-29.
24. Chang TT, Gish RG, de Man RA, et al,. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
25. Kim HJ, Park DI, Park JH, et al,. Comparison between clevudine and entecavir treatment for antiviral-naive patients with chronic hepatitis B. Liver Int 2010; 30: 834-40.
26. Kobashi H, Takaguchi K, Ikeda H, et al,. Efficacy and safety of entecavir in nucleoside-naive, chronic hepatitis B patients: phase II clinical study in Japan. J Gastroenterol Hepatol 2009; 24: 255-61.
27. Lai CL, Rosmawati M, Lao J, et al,. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123: 1831-8.
28. Ren FY, Piao DM, Piao XX,. A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol 2007; 13: 4264-7.
29. Ridruejo E, Adrover R, Cocozzella D, et al,. Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice. Int J Clin Pract 2011; 65: 866-70.
30. Tsai MC, Lee CM, Chiu KW, et al,. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice. J Antimicrob Chemother 2012; 67: 696-9.
31. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL,. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: viral suppression, viral resistance, and clinical safety. Am J Gastroenterol 2011; 106: 1264-71.
32. Marcellin P, Heathcote EJ, Buti M, et al,. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
33. Gordon SC, Krastev Z, Horban A, et al,. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology 2013; 58: 505-13.